Biotech Values

[dewophile]

Yes, although the data in HRp is not as robust. This is where CLVS may get the most traction commercially down the road but with all the slicing and dicing of the data they didn't give an update here and all you can do is guess based on ITT vs BRCAm/HRD the benefit in the HRp.